Comparing different non-invasive brain stimulation interventions for bipolar depression treatment: A network meta-analysis of randomized controlled trials

Imagem de Miniatura
Arquivos
art_HSU_Comparing_different_noninvasive_brain_stimulation_interventions_for_bipolar_2024.PDF (1.75 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
HSU, Chih-Wei
CHOU, Po-Han
HUNG, Kuo-Chuan
TSENG, Ping-Tao
LIANG, Chih-Sung
CARVALHO, Andre F.
VIETA, Eduard
TU, Yu-Kang
LIN, Pao-Yen
Citação
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, v.156, article ID 105483, 10p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Non-invasive brain stimulation (NIBS) is a promising treatment for bipolar depression. We systematically searched for randomized controlled trials on NIBS for treating bipolar depression (INPLASY No: 202340019). Eighteen articles (N = 617) were eligible for network meta-analysis. Effect sizes were reported as standardized mean differences (SMDs) or odds ratios (ORs) with 95% confidence intervals (CIs). Anodal transcranial direct current stimulation over F3 plus cathodal transcranial direct current stimulation over F4 (a-tDCS-F3 +c-tDCS-F4; SMD =-1.18, 95%CIs =-1.66 to-0.69, N = 77), high-definition tDCS over F3 (HD-tDCS-F3;-1.17,-2.00 to 0.35, 25), high frequency deep transcranial magnetic stimulation (HF-dTMS;-0.81,-1.62 to-0.001, 25), and high frequency repetitive TMS over F3 plus low frequency repetitive TMS over F4 (HF-rTMS-F3 +LF-rTMS-F4; 0.77,-1.43 to-0.11, 38) significantly improved depressive symptoms compared to sham controls. Only atDCS-F3 +c-tDCS-F4 (OR = 4.53, 95%CIs = 1.51-13.65) and HF-rTMS-F3 +LF-rTMS-F4 (4.69, 1.02-21.56) showed higher response rates. No active NIBS interventions exhibited significant differences in dropout or side effect rates, compared with sham controls.
Palavras-chave
Antidepressant, Bipolar disorder, Theta burst stimulation, Transcranial electrical stimulation
URI
https://observatorio.fm.usp.br/handle/OPI/57835
Referências
  1. Bortolomasi M, 2007, PSYCHIAT RES, V150, P181, DOI 10.1016/j.psychres.2006.04.010
  2. Bulteau S, 2019, NEUROPHYSIOL CLIN, V49, P371, DOI 10.1016/j.neucli.2019.10.002
  3. Camprodon JA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.1055
  4. Carvalho AF, 2020, NEW ENGL J MED, V383, P58, DOI 10.1056/NEJMra1906193
  5. Chen JJ, 2023, CNS DRUGS, V37, P837, DOI 10.1007/s40263-023-01037-0
  6. Cheng CM, 2023, ASIAN J PSYCHIATR, V82, DOI 10.1016/j.ajp.2023.103480
  7. Dolbert OT, 2002, BIPOLAR DISORD, V4, P94, DOI 10.1034/j.1399-5618.4.s1.41.x
  8. Dondé C, 2017, PROG NEURO-PSYCHOPH, V78, P123, DOI 10.1016/j.pnpbp.2017.05.021
  9. Ellard KK., 2021, The Neuroscience of Depression, P277
  10. Elyamany O, 2021, EUR ARCH PSY CLIN N, V271, P135, DOI 10.1007/s00406-020-01209-9
  11. Feifel D, 2016, JOVE-J VIS EXP, DOI 10.3791/53858
  12. Fitzgerald PB, 2016, J AFFECT DISORDERS, V198, P158, DOI 10.1016/j.jad.2016.03.052
  13. Fitzgerald PB, 2003, ARCH GEN PSYCHIAT, V60, P1002, DOI 10.1001/archpsyc.60.9.1002
  14. Fitzgerald PB, 2006, AM J PSYCHIAT, V163, P88, DOI 10.1176/appi.ajp.163.1.88
  15. Fountoulakis KN, 2020, INT J NEUROPSYCHOPH, V23, P230, DOI 10.1093/ijnp/pyz064
  16. Hernández-Ribas R, 2013, BRAIN STIMUL, V6, P54, DOI 10.1016/j.brs.2012.01.001
  17. Herwig U, 2007, BRIT J PSYCHIAT, V191, P441, DOI 10.1192/bjp.bp.106.034371
  18. Hett D, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320973790
  19. Higgins JP, 2014, VALUE HEALTH, V17, pA324, DOI 10.1016/j.jval.2014.08.572
  20. Hu SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep30537
  21. Huang MH, 2023, AM J GERIAT PSYCHIAT, V31, P1062, DOI 10.1016/j.jagp.2023.06.013
  22. Ilzarbe L, 2023, EUR NEUROPSYCHOPHARM, V71, P6, DOI 10.1016/j.euroneuro.2023.03.001
  23. Jog MA, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-29792-6
  24. Judd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530
  25. Judd LL, 2003, ARCH GEN PSYCHIAT, V60, P261, DOI 10.1001/archpsyc.60.3.261
  26. Kazemi R, 2016, PSYCHIAT RES, V240, P364, DOI 10.1016/j.psychres.2016.04.061
  27. Kimbrell TA, 1999, BIOL PSYCHIAT, V46, P1603, DOI 10.1016/S0006-3223(99)00195-X
  28. Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315
  29. Klomjai W, 2015, ANN PHYS REHABIL MED, V58, P208, DOI 10.1016/j.rehab.2015.05.005
  30. Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930
  31. Lee JW, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.969199
  32. Loo CK, 2018, BRAIN STIMUL, V11, P125, DOI 10.1016/j.brs.2017.10.011
  33. Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634
  34. Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
  35. Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
  36. Mak ADP, 2021, INT J BIPOLAR DISORD, V9, DOI 10.1186/s40345-021-00245-1
  37. Mallik G, 2023, J ECT, V39, P28, DOI 10.1097/YCT.0000000000000870
  38. Mardani P, 2021, BMC PSYCHIATRY, V21, DOI 10.1186/s12888-021-03592-6
  39. Matsuda Y, 2020, NEUROPSYCHOBIOLOGY, V79, P208, DOI 10.1159/000505405
  40. McClure D, 2015, J NERV MENT DIS, V203, P827, DOI 10.1097/NMD.0000000000000378
  41. McGirr A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0963
  42. McIntyre RS, 2021, J AFFECT DISORDERS, V293, P73, DOI 10.1016/j.jad.2021.05.075
  43. Merikangas KR, 2011, ARCH GEN PSYCHIAT, V68, P241, DOI 10.1001/archgenpsychiatry.2011.12
  44. Mutz J, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l1079
  45. Nahas Z, 2003, BIPOLAR DISORD, V5, P40, DOI 10.1034/j.1399-5618.2003.00011.x
  46. Nguyen TD, 2021, J AFFECT DISORDERS, V279, P250, DOI 10.1016/j.jad.2020.10.013
  47. Page MJ, 2021, J CLIN EPIDEMIOL, V134, P178, DOI [10.1136/bmj.n160, 10.1016/j.jclinepi.2021.03.001, 10.1016/j.jclinepi.2021.02.003, 10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]
  48. Pallanti S, 2021, EUR NEUROPSYCHOPHARM, V52, P72, DOI 10.1016/j.euroneuro.2021.07.002
  49. Pallanti S, 2021, EUR NEUROPSYCHOPHARM, V45, P38, DOI 10.1016/j.euroneuro.2021.03.004
  50. Pastrnak M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96319-2
  51. Pell GS, 2022, J CLIN MED, V11, DOI 10.3390/jcm11041015
  52. Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630
  53. Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
  54. Sampaio B Jr, 2018, JAMA PSYCHIAT, V75, P158, DOI 10.1001/jamapsychiatry.2017.4040
  55. Speer AM, 2014, BRAIN STIMUL, V7, P36, DOI 10.1016/j.brs.2013.07.004
  56. Tavares DF, 2017, NEUROPSYCHOPHARMACOL, V42, P2593, DOI 10.1038/npp.2017.26
  57. Tseng P.T., 2022, JAMA Psychiatry.
  58. Tseng PT, 2022, JAMA PSYCHIAT, V79, P770, DOI 10.1001/jamapsychiatry.2022.1513
  59. Tu YK, 2014, MED DECIS MAKING, V34, P911, DOI 10.1177/0272989X14545789
  60. White IR, 2015, STATA J, V15, P951, DOI 10.1177/1536867X1501500403
  61. Yang LL, 2019, J AFFECT DISORDERS, V246, P851, DOI 10.1016/j.jad.2018.12.102
  62. Yatham LN, 2018, BIPOLAR DISORD, V20, P97, DOI 10.1111/bdi.12609
  63. Zengin G, 2022, PSYCHIAT DANUB, V34, P236, DOI 10.24869/psyd.2022.236
  64. Zhang L, 2023, J AFFECT DISORDERS, V323, P570, DOI 10.1016/j.jad.2022.12.007
  65. Zibman S, 2021, EUR NEUROPSYCHOPHARM, V45, P73, DOI 10.1016/j.euroneuro.2019.06.009

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/27